Andecaliximab not checked

Ashibio Inc

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Participants will receive weekly subcutaneous injections of andecaliximab during inpatient hospitalization, clinic visit, or self-administration if discharged from the hospital”In the company’s words, NCT07024407 on ClinicalTrials.gov
Tested for
Fibrodysplasia Ossificans Progressiva, Heterotopic Ossification (HO)
Main trialPhase 2/3
“This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP. The study is looking at several research questions, including: * Safety of andecaliximab in participants with FOP * Whether andecaliximab reduces the number of new heterotopic bone lesions (Heterotopic Ossification; HO) * Whether andecaliximab reduces the number or severity of flare-ups * Pharmacokinetics/pharmacodynamics (PK/PD): How…”In the company’s words, NCT06508021 on ClinicalTrials.gov

Other drugs for Fibrodysplasia Ossificans Progressiva

All 3 drugs for Fibrodysplasia Ossificans Progressiva

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2/3Active, not recruiting 4 Feb 2029 A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Phase 1/2Active, not recruiting Dec 2028 A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Andecaliximab

Following is part of Solo: you see every change to Andecaliximab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in